Biomarkers /
FANCM
Overview
Fanconi anemia complementation group M (FANCM) is a gene that encodes a protein that functions in DNA repair. Missense mutations, synonymous mutations, frameshift deletions, nonsense mutations, and frameshift insertions are observed in cancers such as colon cancer, endometrial cancer, and stomach cancer.
FANCM is altered in 5.06% of all cancers with lung adenocarcinoma, colon adenocarcinoma, melanoma, glioblastoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in FANCM are FANCM Mutation (4.93%), FANCM Nonsense (0.45%), FANCM Frameshift (0.37%), FANCM V1336fs (0.16%), and FANCM I259V (0.11%) [3].
Clinical Trials
Significance of FANCM in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.